With the 2026 implementation of maximum fair prices on selected anticoagulants, we modeled potential effects on rates of treatment for Medicare Part D beneficiaries.
25 April 2024 - by Palak Desai, Jessica Naber, Prachi Bhatt, Tyler Engel
CMS’s Cell and Gene Therapy Access Model offers Medicaid programs increased access to the treatment while addressing complexities and financial uncertainties.